Revvity, Inc. (RVTY) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-24

How it makes money

It generates $2,856.1 million by supplying reagents, automated liquid handlers, and software like ChemDraw to pharmaceutical researchers and diagnostic laboratories.

Profits are divided between Life Sciences ($1,431.1 million) and Diagnostics ($1,424.9 million). Software revenue, including the Signals Research platform, increased by $35.6 million in 2025, which helped offset a slight decrease in other life science solutions.

The business model relies on a mix of capital equipment sales and high-volume consumables. Diagnostics growth is driven by Immunodiagnostics and Reproductive Health, while Life Sciences earns through high-margin software licenses and proprietary reagents like AlphaLISA and BioLegend antibodies.

What protects it: the moat

It secures its position through proprietary technologies like HTRF and AlphaLISA, which require its own microplate readers for high-throughput screening applications.

The business maintains a catalog of over 35,000 SKUs under the BioLegend brand, providing specialized antibodies and reagents that are deeply embedded in research protocols.

Switching costs are reinforced by software platforms like Signals Notebook and Specimen Gate, which manage critical genomic and diagnostic data for hospitals and medical labs. Specialized diagnostic capabilities, such as the T-SPOT.TB test for tuberculosis, provide unique market positions that are harder for generic competitors to penetrate.

What growth costs

Reinvestment focus includes $215.8 million in research and development and $73.5 million for capital expenditures to expand manufacturing and digital capabilities.

To maintain its competitive edge, it spent $215.8 million on research and development in 2025, representing 7.6% of its total revenue.

Profitability is supported by aggressive cost containment, including $55.9 million in restructuring charges related to facility consolidations and a workforce reduction of approximately 5% during 2025. The company also continues to integrate major acquisitions like BioLegend, which involves ongoing stock compensation and transition expenses.

What could damage it

Unfavorable diagnostic testing policy changes in China and $20 million in net tariff impacts from European manufacturing reduced 2025 operating margins.

Operating margins in the Diagnostics segment fell by 194 basis points due to policy shifts in China and increased costs from tariffs on European-made products sold in the U.S. market.

The company is also highly sensitive to the fluid nature of government and academic grant cycles; uncertainties in funding approvals can lead to more conservative spending by customers and delays in both instrumentation and consumable purchases.

About Revvity, Inc.

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

More on RVTY

Other companies in Diagnostics & Research